Optimizing Venetoclax Treatment of Acute Myeloid Leukemia

Download PQI pdf 3.19MB

Last Updated: December 1, 2024

By: Maryland Oncology Hematology, MD | Willamette Valley Cancer Center, OR | Rocky Mountain Cancer Center, CO

About this PQI in Action

This PQI in Action is a follow up to the Optimizing Venetoclax Treatment of Acute Myeloid Leukemia and explores how the medically integrated teams at Maryland Oncology Hematology, Willamette Valley Cancer Center, and Rocky Mountain Cancer Center collaborate and utilize the information found in the PQI as part of their daily practice. This PQI in Action focuses on the use of venetoclax in combination with a hypomethylating agent (HMA; azacitidine or decitabine).

Frequently Searched

Supported by

Optimizing Venetoclax Treatment of Acute Myeloid Leukemia

About this PQI in Action

More About This PQI in Action

PQI in Action: Venetoclax (Venclexta®) Use in Chronic Lymphocytic Leukemia

PQI in Action: Venetoclax (Venclexta®) for the Treatment of Acute Myeloid Leukemia

PQI: Optimizing Venetoclax Treatment of Acute Myeloid Leukemia

PQI: Venetoclax (Venclexta®) Use in Chronic Lymphocytic Leukemia

PQI: Venetoclax (Venclexta®) for the Treatment of Acute Myeloid Leukemia

PQI Podcast S5 Ep 10: Pharmacy Path & NCODA Venetoclax Resources